Search

Clear all

Refine your search

Content type
Tags
Author
Territory
Jurisdiction
Language

916 results found

Smart & Biggar logo
Smart & Biggar is Canada's largest firm practising exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montreal…
Article

Smart & Biggar | Canada | 12 Apr 2021

No more chasing rainbows: advantages of black and white when filing Canadian trademark applications

Some foreign brand owners may be surprised to learn that in Canada, when seeking to protect design (or figurative) marks, it is sometimes better to…
Article

Smart & Biggar | Canada | 5 Apr 2021

Patentability of diagnostic methods - has the Patent Office drawn the line?

The COVID-19 pandemic has highlighted the importance of medical diagnostic technologies. The media frequently reports on matters of…
Article

Smart & Biggar | Canada | 31 Mar 2021

Federal Court of Appeal affirms prohibition order against Apotex regarding abiraterone

As previously reported, in the final decision released under the pre-amended Patented Medicines (Notice of Compliance) Regulations (Regulations), the…
Article

Smart & Biggar | Canada | 31 Mar 2021

Health Canada Consultation on Electronic Media in Prescription Drug Labelling

On March 12, 2021, Health Canada released for consultation its new Draft Guidance Document on Electronic media in prescription drug labelling. The…
Article

Smart & Biggar | Canada | 30 Mar 2021

PMPRB Updates: Definition of “Gap Medicine” amended, modified threshold for investigating the price of new patented medicines

On March 17, 2021 the Patented Medicine Prices Review Board (PMPRB) announced the result of the Consultation opened in January…
Article

Smart & Biggar | Canada | 30 Mar 2021

Federal Court denies stay of decision issuing NOC for RUZURGI

On September 30, 2020, the Federal Court dismissed an application by Catalyst Pharmaceuticals Inc (Catalyst) and KYE Pharmaceuticals Inc (KYE)…
Article

Smart & Biggar | Canada | 30 Mar 2021

Federal Court of Appeal upholds Federal Court decision finding Shire’s VYVANSE patent valid

The Federal Court of Appeal (FCA) recently dismissed an appeal by Apotex from a decision of the Federal Court (see our article here) holding that the…
Article

Smart & Biggar | Canada | 30 Mar 2021

Ontario Superior Court dismisses Apotex’s Statutes of Monopolies and Trademarks Act claims regarding olanzapine

On March 8, 2021, the Ontario Superior Court of Justice granted Eli Lilly's (Lilly) motion for summary judgment and dismissed Apotex's claims under…
Article

Smart & Biggar | Global | 29 Mar 2021

Protecting innovations through patent due diligence and FTO analysis

Innovations that arise in competitive markets with a well-developed and rapidly evolving IP space often integrate several pre-existing Technologies…
Article

Smart & Biggar | Canada | 29 Mar 2021

New CADTH Report on Health Technology Trends in 2021

The Canadian Agency for Drugs and Technologies in Health (CADTH) published an interesting new report on January 29, 2021 about Health Technology…
Previous page 1 2 3 ...